CELL:TBL1XR1突变通驱动结外淋巴瘤的发生 

2020-07-05 MedSci原创 MedSci原创

最具侵袭性的B细胞淋巴瘤经常表现为体外分布,并携带特征不明显的TBL1XR1基因的体细胞突变。

最具侵袭性的B细胞淋巴瘤经常表现为体外分布,并携带特征不明显的TBL1XR1基因的体细胞突变。

最近,研究人员表明,TBL1XR1突变使体液免疫反应偏向于产生异常的不成熟记忆B细胞(MB),同时损害浆细胞分化。

在分子水平上,TBL1XR1突变体与SMRT/HDAC3抑制复合物共同作用,结合MB细胞转录因子(TF)BACH2,而牺牲生殖中心(GC)转录因子BCL6,导致前记忆转录重编程和细胞命运偏差。

抗原回收后,TBL1XR1突变MB细胞不能分化为浆细胞,而是优先重新进入新的GC反应,为循环重入淋巴发生机制提供了证据。

最终,TBL1XR1的改变导致了一种惊人的外胚层免疫细胞淋巴瘤表型,模仿了人类疾病。

人和鼠淋巴瘤都具有扩大的MB样细胞群,其与MB细胞起源一致,并揭示了免疫系统恶性转化的不可预见的途径。

 

原始出处:

Leandro Venturutti et al. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate, CELL (2020). DOI:https://doi.org/10.1016/j.cell.2020.05.049

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1962127, encodeId=bd86196212e6f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 22 22:53:35 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871830, encodeId=d1cb18e18304d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Sep 15 08:53:35 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801304, encodeId=6898801304e7, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b34e2780430, createdName=522670496, createdTime=Sun Jul 05 12:41:53 CST 2020, time=2020-07-05, status=1, ipAttribution=)]
    2021-04-22 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1962127, encodeId=bd86196212e6f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 22 22:53:35 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871830, encodeId=d1cb18e18304d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Sep 15 08:53:35 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801304, encodeId=6898801304e7, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b34e2780430, createdName=522670496, createdTime=Sun Jul 05 12:41:53 CST 2020, time=2020-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1962127, encodeId=bd86196212e6f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 22 22:53:35 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871830, encodeId=d1cb18e18304d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Sep 15 08:53:35 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801304, encodeId=6898801304e7, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b34e2780430, createdName=522670496, createdTime=Sun Jul 05 12:41:53 CST 2020, time=2020-07-05, status=1, ipAttribution=)]
    2020-07-05 522670496

    很有收获

    0